These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 17060589)

  • 1. Parkinsonism, Lrrk2 G2019S, and tau neuropathology.
    Rajput A; Dickson DW; Robinson CA; Ross OA; Dächsel JC; Lincoln SJ; Cobb SA; Rajput ML; Farrer MJ
    Neurology; 2006 Oct; 67(8):1506-8. PubMed ID: 17060589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
    Gaig C; Ezquerra M; Martí MJ; Valldeoriola F; Muñoz E; Lladó A; Rey MJ; Cardozo A; Molinuevo JL; Tolosa E
    J Neurol Sci; 2008 Jul; 270(1-2):94-8. PubMed ID: 18353371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau.
    Taymans JM; Cookson MR
    Bioessays; 2010 Mar; 32(3):227-235. PubMed ID: 20127702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2.
    Devine MJ; Lewis PA
    FEBS J; 2008 Dec; 275(23):5748-57. PubMed ID: 19021752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-occurrence of sporadic parkinsonism and late-onset Alzheimer's disease in a Brazilian male with the LRRK2 p.G2019S mutation.
    Santos-Rebouças CB; Abdalla CB; Baldi FJ; Martins PA; Corrêa JC; Gonçalves AP; Cunha MS; Borges MB; Pereira JS; Laks J; Pimentel MM
    Genet Test; 2008 Dec; 12(4):471-3. PubMed ID: 19072560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.
    Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R
    Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical tauopathy in a patient with LRRK2-G2019S mutation and tremor-dominant Parkinsonism.
    Ruffmann C; Giaccone G; Canesi M; Bramerio M; Goldwurm S; Gambacorta M; Rossi G; Tagliavini F; Pezzoli G
    Neuropathol Appl Neurobiol; 2012 Jun; 38(4):382-6. PubMed ID: 21883375
    [No Abstract]   [Full Text] [Related]  

  • 8. Biochemical and pathological characterization of Lrrk2.
    Giasson BI; Covy JP; Bonini NM; Hurtig HI; Farrer MJ; Trojanowski JQ; Van Deerlin VM
    Ann Neurol; 2006 Feb; 59(2):315-22. PubMed ID: 16437584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain.
    González-Fernández MC; Lezcano E; Ross OA; Gómez-Esteban JC; Gómez-Busto F; Velasco F; Alvarez-Alvarez M; Rodríguez-Martínez MB; Ciordia R; Zarranz JJ; Farrer MJ; Mata IF; de Pancorbo MM
    Parkinsonism Relat Disord; 2007 Dec; 13(8):509-15. PubMed ID: 17540608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.
    Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V
    Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.
    Zimprich A; Biskup S; Leitner P; Lichtner P; Farrer M; Lincoln S; Kachergus J; Hulihan M; Uitti RJ; Calne DB; Stoessl AJ; Pfeiffer RF; Patenge N; Carbajal IC; Vieregge P; Asmus F; Müller-Myhsok B; Dickson DW; Meitinger T; Strom TM; Wszolek ZK; Gasser T
    Neuron; 2004 Nov; 44(4):601-7. PubMed ID: 15541309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's Disease Associated with G2019S LRRK2 Mutations without Lewy Body Pathology.
    Jackson LM; Woodruff BK; Tremblay C; Shill HA; Beach TG; Serrano GE; Adler CH
    Mov Disord Clin Pract; 2024 Jul; 11(7):874-878. PubMed ID: 38757351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unilateral pallidotomy in a patient with parkinsonism and G2019S LRRK2 mutation.
    Munhoz RP; Teive HA; Francisco AN; Raskin S; Rogaeva E
    Mov Disord; 2009 Apr; 24(5):791-2; author reply 792. PubMed ID: 19012346
    [No Abstract]   [Full Text] [Related]  

  • 14. Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations.
    Schüpbach M; Lohmann E; Anheim M; Lesage S; Czernecki V; Yaici S; Worbe Y; Charles P; Welter ML; Pollak P; Dürr A; Agid Y; Brice A
    Mov Disord; 2007 Jan; 22(1):119-22. PubMed ID: 17080443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?
    Taylor JP; Mata IF; Farrer MJ
    Trends Mol Med; 2006 Feb; 12(2):76-82. PubMed ID: 16406842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT.
    Ling H; Kara E; Bandopadhyay R; Hardy J; Holton J; Xiromerisiou G; Lees A; Houlden H; Revesz T
    Neurobiol Aging; 2013 Dec; 34(12):2889.e5-9. PubMed ID: 23664753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early-onset familial lewy body dementia with extensive tauopathy: a clinical, genetic, and neuropathological study.
    Clarimón J; Molina-Porcel L; Gómez-Isla T; Blesa R; Guardia-Laguarta C; González-Neira A; Estorch M; Ma Grau J; Barraquer L; Roig C; Ferrer I; Lleó A
    J Neuropathol Exp Neurol; 2009 Jan; 68(1):73-82. PubMed ID: 19104444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism.
    van Nuenen BF; Helmich RC; Ferraye M; Thaler A; Hendler T; Orr-Urtreger A; Mirelman A; Bressman S; Marder KS; Giladi N; van de Warrenburg BP; Bloem BR; Toni I;
    Brain; 2012 Dec; 135(Pt 12):3687-98. PubMed ID: 23250886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRRK2 I2020T mutation is associated with tau pathology.
    Ujiie S; Hatano T; Kubo S; Imai S; Sato S; Uchihara T; Yagishita S; Hasegawa K; Kowa H; Sakai F; Hattori N
    Parkinsonism Relat Disord; 2012 Aug; 18(7):819-23. PubMed ID: 22525366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olfactory heterogeneity in LRRK2 related Parkinsonism.
    Silveira-Moriyama L; Munhoz RP; de J Carvalho M; Raskin S; Rogaeva E; de C Aguiar P; Bressan RA; Felicio AC; Barsottini OG; Andrade LA; Chien HF; Bonifati V; Barbosa ER; Teive HA; Lees AJ
    Mov Disord; 2010 Dec; 25(16):2879-83. PubMed ID: 20818658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.